Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395305 | 1.00 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL30429412 | 0.92 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1785290 | 0.92 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL7162438 | 0.90 | MAOB (0.62) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL2801030 | 0.88 | MAOB (0.60) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL13883739 | 0.87 | MAOB (0.64) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL2870704 | 0.85 | MAOB (0.53) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1685431 | 0.85 | KCNA3 (0.50) | HTTKMT2ALMNA | |
| SCHEMBL3792473 | 0.84 | MAOB (0.56) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL2431860 | 0.83 | MAOB (0.60) | MAOBRAB9AHTTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| CN-112424194-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-109863146-B | Biaryl compounds as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | MAOB 4588/4885RAB9A 1581/4885HTT 261/4885 |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | MAOB 542/4885RAB9A 3072/4885HTT 107/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | MAOB 4588/4885RAB9A 1581/4885HTT 261/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MAOB 3560/4885RAB9A 2065/4885HTT 572/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | MAOB 3663/4885RAB9A 3237/4885HTT 1936/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | MAOB 4465/4885RAB9A 1198/4885HTT 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.